| P2093 | author name string | David S Perlin | |
| P2860 | cites work | A drug-sensitive genetic network masks fungi from the immune system | Q21131621 |
| | Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin | Q24674839 |
| | Micafungin: an evidence-based review of its place in therapy | Q27014780 |
| | The yeast FKS1 gene encodes a novel membrane protein, mutations in which confer FK506 and cyclosporin A hypersensitivity and calcineurin-dependent growth | Q27934297 |
| | Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin | Q28475818 |
| | Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata | Q28483785 |
| | Echinocandin resistance: an emerging clinical problem? | Q28544739 |
| | Hidden killers: human fungal infections | Q29617101 |
| | Mucosal damage and neutropenia are required for Candida albicans dissemination | Q33320189 |
| | Stimulation of chitin synthesis rescues Candida albicans from echinocandins. | Q33326983 |
| | Functional analysis of Candida albicans GPI-anchored proteins: roles in cell wall integrity and caspofungin sensitivity | Q33365853 |
| | Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole | Q33622915 |
| | Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. | Q33830384 |
| | Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. | Q38195132 |
| | Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management | Q38254290 |
| | Mechanisms of Antifungal Drug Resistance | Q38266675 |
| | A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility | Q39686624 |
| | Role of matrix β-1,3 glucan in antifungal resistance of non-albicans Candida biofilms. | Q39767233 |
| | The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial | Q39878330 |
| | Development of echinocandin-resistant Candida albicans candidemia following brief prophylactic exposure to micafungin therapy | Q40207847 |
| | Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains | Q40750655 |
| | Risk factors for candidemia in patients with acute lymphocytic leukemia | Q40751044 |
| | Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance | Q41184732 |
| | Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints | Q41787736 |
| | In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. | Q41810114 |
| | The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. | Q41810708 |
| | Fungal echinocandin resistance. | Q41848811 |
| | Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria | Q41908678 |
| | Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. | Q41990022 |
| | Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae | Q42035911 |
| | Aneuploidy and isochromosome formation in drug-resistant Candida albicans | Q42113364 |
| | The impact of new epidemiological cutoff values on Candida glabrata resistance rates and concordance between testing methods | Q42222742 |
| | Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis | Q42232412 |
| | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint | Q42545839 |
| | Candida glabrata intra-abdominal candidiasis is characterized by persistence within the peritoneal cavity and abscesses | Q42735489 |
| | Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. | Q42929579 |
| | Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria | Q43125888 |
| | Candida colonisation as a source for candidaemia | Q44703269 |
| | Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy? | Q46908055 |
| | EUCAST technical note on anidulafungin | Q47577071 |
| | A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade | Q61024374 |
| | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species | Q33876423 |
| | Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates | Q33938068 |
| | Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance | Q34058099 |
| | Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies | Q34301513 |
| | Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients | Q34529026 |
| | Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy | Q34754956 |
| | Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | Q34936576 |
| | Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin | Q35065859 |
| | Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. | Q35129428 |
| | Candida glabrata mutants demonstrating paradoxical reduced caspofungin susceptibility but increased micafungin susceptibility | Q35139474 |
| | New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species | Q35139501 |
| | Importance of Candida-bacterial polymicrobial biofilms in disease | Q35490098 |
| | Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo | Q35666505 |
| | Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata | Q35867789 |
| | Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations | Q35941237 |
| | Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia | Q35947465 |
| | Integrative studies put cell wall synthesis on the yeast functional map. | Q35958175 |
| | Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates | Q36095337 |
| | The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata | Q36172500 |
| | Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. | Q36423773 |
| | Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin. | Q36785949 |
| | Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. | Q36845482 |
| | Resistance to echinocandin-class antifungal drugs | Q36849595 |
| | Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations | Q36856930 |
| | Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. | Q36933000 |
| | Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. | Q36983268 |
| | Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. | Q37015953 |
| | Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geogr | Q37036246 |
| | Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. | Q37124005 |
| | Investigation of the sequence of colonization and candidemia in nonneutropenic patients | Q37165273 |
| | Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? | Q37335747 |
| | Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method. | Q37544819 |
| | Current perspectives on echinocandin class drugs | Q37554055 |
| | Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections | Q38053482 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | S612-7 | |
| P577 | publication date | 2015-12-01 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Echinocandin Resistance in Candida | |
| P478 | volume | 61 Suppl 6 | |